EMA Authorised: Elfabrio (pegunigalsidase alfa) — Chiesi Farmaceutici S.p.A

View source ↗

Summary

EMA authorised Elfabrio (pegunigalsidase alfa) from Chiesi Farmaceutici S.p.A for Fabry disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• Elfabrio (migalastat)

Snippet

Status: Authorised. Therapeutic area: Fabry Disease. MAH: Chiesi Farmaceutici S.p.A. Decision date: 05/03/2026